AI assistant
Safe S.A. Share Issue/Capital Change 2019
1638_rns_2019-07-15_67e73ce7-f2e2-4a06-8b1c-20ea8c4e98f3.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets
Eragny-sur-Oise, France, July 15, 2019 – 08h35 CEST – Safe Orthopaedics (FR0012452746 - SAFOR), a company specializing in the design and marketing of single-use implants and instruments for the minimally invasive treatment of spinal fracture conditions, is today releasing its half-year report on the liquidity contract signed with Louis Capital Markets on June 1, 2018.
The liquidity account had the following holdings as of June 30, 2019:
-
77 246 shares
-
6 926,35 euros
During the first half of 2019, the following have been negotiated:
| PURCHASE | 182 651 shares | 27 721,61 euros | 257 transactions |
|---|---|---|---|
| SALE | 201 793 shares | 32 248,03 euros | 248 transactions |
For the prior period (December 31, 2018), the corresponding figures were:
- 96 388 shares
- 3 610,46 euros
As of March 18, 2019 (implementation of the new liquidity contract), the followings were made available:
-
74 738 shares
-
7 561,33 euros
Next financial publication: 2019 half-year result, September 27, 2019 (after the market close)
About Safe Orthopaedics
Founded in 2010, Safe Orthopaedics, is a French medical technology company that offers the safest technologies to treat spinal fractures. Delivered sterile, all implants and respective disposable instrumentation are available to the surgeon at any time, anywhere. These technologies enable minimally invasive approaches, redcucing risks of cross contamination and infection in the interest of the patient. Protected by 17 patent families, SteriSpineTM kits are CE marked and FDA cleared. The company is based in Eragny-sur-Oise (95) and has 50 employees.
For more information: www.SafeOrthopaedics.com
PRESS RELEASE
Contacts
Safe Orthopaedics François-Henri Reynaud CFO Tél. : +33 (0)1 34 21 50 00 [email protected]
Investor Relations NewCap Mathilde Bohin Tél. : +33 (0)1 44 71 94 94 / [email protected]
Press Relations
Ulysse Communication Bruno Arabian / +33 (0)6 87 88 47 26 / [email protected] Nicolas Daniels / +33 (0)6 63 66 59 22 / [email protected]